Company intelligence / Profile preview
Biosantech
Sophia Antipolis, Provence-Alpes-Cote d'Azur, Francebiosantech.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biosantech is a private French biopharmaceutical company focused on developing a therapeutic HIV vaccine. The company is best known for Tat Oyi, a synthetic protein vaccine candidate designed to target the HIV Tat protein and potentially control viral rebound in people living with HIV after treatment interruption. Biosantech has sponsored a Phase I/II clinical study of this candidate in seropositive patients and has presented results suggesting immunogenicity and an effect on viral rebound. The company appears to be a small, single-asset biotech centered on HIV/AIDS research rather than a diversified platform business.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineProtein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Biosantech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosantech.